198 related articles for article (PubMed ID: 17883249)
1. beta-cell function and anti-diabetic pharmacotherapy.
Del Prato S; Bianchi C; Marchetti P
Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
[TBL] [Abstract][Full Text] [Related]
2. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
Raskin P
Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
[TBL] [Abstract][Full Text] [Related]
3. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
4. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.
Lupi R; Del Prato S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S56-64. PubMed ID: 18640587
[TBL] [Abstract][Full Text] [Related]
5. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
Bermúdez V; Cano R; Cano C; Bermúdez F; Leal E; Acosta K; Mengual E; Arraiz N; Briceño C; Gómez J; Bustamante M; Aparicio D; Cabrera M; Valdelamar L; Rodriguez M; Manuel V; Hernández R
Am J Ther; 2008; 15(4):409-16. PubMed ID: 18645347
[TBL] [Abstract][Full Text] [Related]
6. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?
van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S37-46. PubMed ID: 21864750
[TBL] [Abstract][Full Text] [Related]
7. The importance of beta-cell management in type 2 diabetes.
Standl E
Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
[TBL] [Abstract][Full Text] [Related]
8. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
Massi-Benedetti M; Orsini-Federici M
Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
[TBL] [Abstract][Full Text] [Related]
9. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
10. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
Hanefeld M
Int J Clin Pract Suppl; 2007 Jun; 61(153):20-7. PubMed ID: 17594390
[TBL] [Abstract][Full Text] [Related]
11. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
12. Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth.
Holloway AC; Hettinga BP; Gerstein HC
J Diabetes; 2011 Mar; 3(1):74-81. PubMed ID: 21040499
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis.
Decker M; Hofflich H; Elias AN
Diabetes Obes Metab; 2008 Aug; 10(8):617-25. PubMed ID: 17645549
[TBL] [Abstract][Full Text] [Related]
14. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
15. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
DeFronzo RA
Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
[TBL] [Abstract][Full Text] [Related]
16. Insulin in the early management of diabetic complications.
Miles JM
J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
[TBL] [Abstract][Full Text] [Related]
17. Endoplasmic reticulum stress in beta cells: latent mechanism of secondary sulfonylurea failure in type 2 diabetes?
Qian L; Zhang S; Xu L; Peng Y
Med Hypotheses; 2008 Dec; 71(6):889-91. PubMed ID: 18786775
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
19. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
20. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]